Alembic Pharmaceuticals Limited (APLLTD.BO)
INR 850.0
(0.7%)
INR 850.0
(0.7%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.86 Billion INR | -40.21% |
| 2022 | 6.46 Billion INR | -1.45% |
| 2021 | 6.56 Billion INR | 35.11% |
| 2020 | 4.85 Billion INR | -72.39% |
| 2019 | 17.58 Billion INR | 89.25% |
| 2018 | 9.29 Billion INR | 48.93% |
| 2017 | 6.24 Billion INR | 1066.59% |
| 2016 | -645.6 Million INR | 78.6% |
| 2015 | -3.01 Billion INR | -232.33% |
| 2014 | 2.27 Billion INR | 166.85% |
| 2013 | 854.36 Million INR | -49.95% |
| 2012 | 1.7 Billion INR | -44.15% |
| 2011 | 3.05 Billion INR | 13.84% |
| 2010 | 2.68 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 3.86 Billion INR | -40.21% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 3.86 Billion INR | 0.0% |
| 2023 Q2 | 7.27 Billion INR | 0.0% |
| 2022 Q4 | 6.46 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 6.46 Billion INR | -1.45% |
| 2022 Q2 | 7.05 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 6.56 Billion INR | 35.11% |
| 2021 Q4 | 6.56 Billion INR | 0.0% |
| 2021 Q2 | 8.15 Billion INR | 0.0% |
| 2020 Q4 | 4.85 Billion INR | 0.0% |
| 2020 FY | 4.85 Billion INR | -72.39% |
| 2020 Q2 | 3.27 Billion INR | 0.0% |
| 2019 Q2 | 12.35 Billion INR | 0.0% |
| 2019 Q4 | 17.58 Billion INR | 0.0% |
| 2019 FY | 17.58 Billion INR | 89.25% |
| 2018 FY | 9.29 Billion INR | 48.93% |
| 2018 Q4 | 9.29 Billion INR | 0.0% |
| 2018 Q2 | 10.15 Billion INR | 0.0% |
| 2017 Q4 | 6.24 Billion INR | 0.0% |
| 2017 Q2 | 2.12 Billion INR | 0.0% |
| 2017 FY | 6.24 Billion INR | 1066.59% |
| 2016 Q4 | -645.6 Million INR | 0.0% |
| 2016 FY | -645.6 Million INR | 78.6% |
| 2016 Q2 | -1.99 Billion INR | 0.0% |
| 2015 FY | -3.01 Billion INR | -232.33% |
| 2015 Q2 | -196.8 Million INR | 0.0% |
| 2015 Q4 | -3.01 Billion INR | 0.0% |
| 2014 Q4 | 2.27 Billion INR | 0.0% |
| 2014 FY | 2.27 Billion INR | 166.85% |
| 2014 Q2 | 1.51 Billion INR | 0.0% |
| 2013 Q4 | 854.36 Million INR | 0.0% |
| 2013 FY | 854.36 Million INR | -49.95% |
| 2013 Q2 | 1.47 Billion INR | 0.0% |
| 2012 Q2 | 1.08 Billion INR | 0.0% |
| 2012 FY | 1.7 Billion INR | -44.15% |
| 2012 Q4 | 1.7 Billion INR | 0.0% |
| 2011 FY | 3.05 Billion INR | 13.84% |
| 2010 FY | 2.68 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aurobindo Pharma Limited | 3.69 Billion INR | -4.673% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 235.996% |
| Granules India Limited | 9.28 Billion INR | 58.372% |
| Indoco Remedies Limited | 6.47 Billion INR | 40.307% |
| Achyut Healthcare Limited | -3.74 Million INR | 103300.747% |
| Ajanta Pharma Limited | -954.9 Million INR | 504.849% |
| Alkem Laboratories Limited | -1.6 Billion INR | 340.208% |
| Alpa Laboratories Limited | 35.36 Million INR | -10832.048% |
| Brooks Laboratories Limited | 49.48 Million INR | -7712.266% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 177.126% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -17.186% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 433.914% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 70.062% |
| Eris Lifesciences Limited | 13.8 Billion INR | 71.999% |
| FDC Limited | -57.75 Million INR | 6793.967% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 190.214% |
| Gufic Biosciences Limited | 3.19 Billion INR | -21.024% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 193.086% |
| Ipca Laboratories Limited | 11.41 Billion INR | 66.134% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 378.136% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -100.003% |
| Lasa Supergenerics Limited | 205.79 Million INR | -1778.483% |
| Laurus Labs Limited | 24.38 Billion INR | 84.146% |
| Lupin Limited | 17.19 Billion INR | 77.514% |
| Mankind Pharma Limited | -9.9 Billion INR | 139.018% |
| Medicamen Biotech Limited | 160.31 Million INR | -2311.425% |
| Medico Remedies Limited | 78.67 Million INR | -4813.634% |
| Megasoft Limited | 1.28 Billion INR | -200.719% |
| NATCO Pharma Limited | -5.81 Billion INR | 166.459% |
| Piramal Pharma Limited | 42.27 Billion INR | 90.856% |
| RPG Life Sciences Limited | -364.7 Million INR | 1160.022% |
| Sigachi Industries Limited | 859.94 Million INR | -349.55% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 105.334% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -2566.579% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -8265.757% |
| Unichem Laboratories Limited | 931.91 Million INR | -314.834% |
| Wanbury Limited | 1.1 Billion INR | -249.578% |
| Windlas Biotech Limited | -273.04 Million INR | 1515.873% |
| ZIM Laboratories Limited | 983.6 Million INR | -293.034% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 1.178% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 510.48% |
| Divi's Laboratories Limited | -39.77 Billion INR | 109.721% |
| Hester Biosciences Limited | 2.29 Billion INR | -68.762% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 264.647% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 1653.868% |
| Bal Pharma Limited | 1.26 Billion INR | -205.953% |
| Strides Pharma Science Limited | 23.25 Billion INR | 83.377% |
| Venus Remedies Limited | -267.7 Million INR | 1544.117% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -48.011% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 37.214% |
| Shilpa Medicare Limited | 9.06 Billion INR | 57.375% |
| Aarti Drugs Limited | 5.54 Billion INR | 30.324% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 451.031% |
| Suven Life Sciences Limited | -1.63 Billion INR | 336.78% |
| Ind-Swift Limited | 9.5 Billion INR | 59.343% |
| Valiant Laboratories Limited | -295.03 Million INR | 1410.332% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -37.03% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 61.453% |
| Themis Medicare Limited | 764.96 Million INR | -405.372% |
| Hikal Limited | 7.96 Billion INR | 51.476% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 87.855% |
| Sequent Scientific Limited | 4.17 Billion INR | 7.484% |
| Novartis India Limited | -5.89 Billion INR | 165.623% |
| Wockhardt Limited | 18.27 Billion INR | 78.84% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 85.72% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 21057.931% |
| Neuland Laboratories Limited | -214.05 Million INR | 1906.006% |
| Morepen Laboratories Limited | -231.17 Million INR | 1772.29% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -3120.537% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -296.173% |